About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
|
|
|
11-50 employees
View all Outlook Therapeutics, Inc. employees
|
|
Biotechnology
|
|
7 Clarke Dr, Cranbury, New Jersey 08512, US
|
|
2011
|
Outlook Therapeutics, Inc. Alternatives
Frequently Asked Questions about Outlook Therapeutics, Inc.
Russ Trenary is the CEO of Outlook Therapeutics, Inc.. To contact Russ Trenary email at [email protected] or [email protected].
The decision makers in Outlook Therapeutics, Inc. are Alicia Tozier, Christopher Yonan, Entisar Dahan, etc. Click to Find Outlook Therapeutics, Inc. decision makers emails.
Outlook Therapeutics, Inc. Staff Directory
Search Outlook Therapeutics, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
